From: Genomic alterations and molecular subtypes of gastric cancers in Asians
Subgroup | Key mutations | Key CNV events | Drugs in development |
---|---|---|---|
MSI | KRAS, PIK3CA (H1047R), PTEN, mTOR, ARID1A | Very few alterations | MEK-ERK and PI3K-mTOR pathway inhibitors, immunotherapies |
MSS/EMT | PIK3CA, RhoA | CCNE1 | PI3K-mTOR, CDK2, and ROCK inhibitors |
MSS/TP53− | TP53 | CCND1, CCNE1, ERBB2, EGFR, KRAS, MYC | RTK-focused agents, MEK-ERK, CDK4/6, and CDK2 inhibitors |
MSS/TP53+ | ARID1A, PIK3CA (E542/545K) | CCNE1, KRAS | MEK-ERK, CDK2, and PI3K-mTOR pathway inhibitors |